Merck Bets $375M on Oral BET Inhibitor With Narrow Signals and Class Toxicity Ceiling
Mergers and Acquisitions

Merck Bets $375M on Oral BET Inhibitor With Narrow Signals and Class Toxicity Ceiling

Published : 19 Nov 2026

At a Glance
IndicationHematological malignancies
DrugOTX015
Mechanism of ActionBET inhibitor
CompanyMerck
Trial PhasePhase 1b
CategoryCorporate & Strategic
Sub CategoryAcquisition Announced
Therapeutic AreaOncology
Acquired CompanyOncoEthix
Deal TypeAcquisition
Upfront Payment$110 million
Milestone Payments$265 million
Target ProteinsBET bromodomain proteins 2/3/4
Patient PopulationPatients with hematological malignancies, advanced solid tumors
Conference PresentationAmerican Association of Cancer Research (AACR) Annual Meeting
Presentation DateApril 2014
Drug In-licensed FromMitsubishi Tanabe Pharma Corporation
In-licensing DateMarch 2012

Merck Acquires OncoEthix, Expands Oncology Pipeline

Merck announced the acquisition of OncoEthix, a Swiss-based oncology company, to expand its oncology portfolio with OTX015, a novel oral BET inhibitor. OTX015 is currently in Phase 1b studies for hematological malignancies and advanced solid tumors, having shown promising early clinical activity. The deal includes an upfront payment of up to $110 million and potential milestone payments of up to $265 million, reinforcing Merck's commitment to developing innovative cancer therapies.

  • Merck's acquisition of OncoEthix is a strategic move to bolster its oncology pipeline with OTX015, a potential first-in-class oral BET inhibitor. This aligns with Merck's focus on developing innovative molecules for advanced cancers and complements its broad immuno-oncology development program, enhancing its presence in a priority therapeutic area.
  • OTX015 is an investigational orally administered synthetic small molecule targeting BET bromodomain proteins 2/3/4. It is currently in Phase 1b clinical studies for hematological malignancies and advanced solid tumors, with interim data presented at AACR 2014 demonstrating meaningful clinical activity in hematological cancers.
  • The financial structure of the acquisition includes an upfront payment of up to $110 million to OncoEthix, with additional milestone payments of up to $265 million contingent upon clinical and regulatory achievements. OncoEthix, founded in 2009, in-licensed OTX015 from Mitsubishi Tanabe Pharma Corporation in March 2012 after initial Phase I studies.

Unlocking Cancer Growth: The Role of BET Proteins

Multiple hematologic malignancies are initiated by defining genetic lesions that cooperate with secondary mutations to drive clonal evolution. These include the t(15;17)(q22;q11.2) chromosomal translocation creating the promyelocytic leukemia-retinoic acid receptor α (PML-RARA) fusion oncogene with cooperating Jak1 V657F, identical to the JAK1 V658F mutation previously found in human APL, and somatic 150-kb deletion involving the lysine (K)-specific demethylase 6A (Kdm6a, also known as Utx) gene, as well as BCR-ABL1 fusion protein from t(9;22)(q34;q11) in chronic myelogenous leukemia, MLL-AF4+ rearrangement in infant ALL, and IDH1 mutations p.R132H, p.R132C, p.R132S, p.R132G, p.R132L and p.I99M and IDH2 mutations p.R140Q and p.R172K with coexisting NPM1 mutations (60-74%). At presentation myeloma is composed of two to six different major clones related by linear and branching phylogenies, with parallel evolution whereby two independent clones activate the RAS/MAPK pathway through RAS mutations, co-occurrence of RAS and interferon regulatory factor 4 (IRF4) p.K123R mutations in 4% of myeloma patients, and progression patterns described as a "static progression model" where subclonal architecture is retained and a "spontaneous evolution model" where change in subclonal composition is observed. Activation-induced cytidine deaminase accelerates clonal evolution in BCR-ABL1 ALL by enhancing genetic instability and aberrant somatic hypermutation and by negative regulation of tumor-suppressor genes including Rhoh, Cdkn1a (p21), and Blnk (SLP65), with AID(-/-) leukemia showing lower frequency of amplifications and deletions and lower frequency of mutations in non-Ig genes including Pax5 and Rhoh, while progression from smoldering stages is driven by APOBEC cytidine deaminases and T-ALL relapse involves drivers MDR1 and MVP, NT5C2 and JAK-STAT activators, IL7R upregulation in type-1 relapse, and BLM, BUB1B/PMS2 and TP53 mutations with hypermutator phenotypes in type-2 relapse.

Epigenetic and transcriptional dysregulation further controls differentiation, proliferation, apoptosis, and malignant transformation. Gene transcriptional activity is regulated by chromatin modification and DNA methylation, with nuclear receptors such as RAR, RXR, and PPARgamma exerting histone acetyl transferase activity (HAT), and histone acetylation by the PPARgamma agonist CDDO, RAR/RXR agonist ATRA, and/or histone deacetylase inhibitors (HDACIs) reversing silenced RARbeta and MDR1 genes in acute promyelocytic leukemia. In HTLV-1-transformed CD4+ T cells, HTLV-1 Tax-induced promoter silencing causes dissociation of Sp1, Oct-1, NF-kappaB, CREB-1, and RNA polymerase II from the core SHP-1 P2 promoter with heavy CpG methylation and decreased expression of the Src homology-2-containing protein-tyrosine phosphatase 1 (SHP-1), a negative regulator of cell signaling considered a tumor suppressor gene for its ability to antagonize tyrosine kinases. Histone modification also mediates response to FK228 (depsipeptide) (0.2-1 ng/mL) through time- and dose-dependent histone H4 hyper-acetylation or histone H3 dephosphorylation and alterations in DNA binding of NF-kappaB, with p53 binding to the p21 (Waf1/Cip1) promotor and induction of Annexin A1 in AML1/ETO-positive acute myelocytic leukemia cells.

The bone marrow microenvironment and leukemia-initiating cell hierarchies sustain persistence, immune evasion, and therapy resistance. Growth factors and integrins interact with receptors and activate signaling cascades with intimate interconnections, with therapeutic interventions focusing on SDF1/CXCR4, ILK/PI3K/Akt, TGF-beta, and Notch signaling, and specific niches within the bone marrow microenvironment providing sanctuary for subpopulations of leukemic cells to escape chemotherapy-induced death and acquire drug resistance. Multiple myeloma originates from the B cell lineage with memory-B cell like features allowing self-renewal and differentiation to monoclonal plasma cells, using signaling pathways and microenvironment similar to the hematopoietic stem cell and inducing quiescence through direct interaction with stroma, with a median of 6 tumor subclones per patient, unique subclones in focal lesions, differential expression of CD20 and CD38, depletion of macrophages in focal lesions, and fluctuations revealing clonal extinction and emergence of new clones. Mature B lymphocytes demonstrate lineage plasticity exemplified by transdifferentiation of follicular lymphomas into clonally related Langerhans cell sarcoma and Langerhans cell histiocytosis, while MLL-AF4+ infant ALL shows dynamic competition between actively proliferating and quiescent subclones with relapses often occurring from subclones already present but more quiescent at diagnosis, and BCR-ABL1 kinase domain mutations including T315I abrogating imatinib binding and rendering leukemia resistant to first- and second-line TKIs.

OTX015's Broad Clinical Potential Across Hematological and Solid Tumors

OTX015 (birabresib/MK-8628), a first-in-class bromodomain inhibitor binding BRD2, BRD3, and BRD4, was evaluated beyond hematologic tumors in a phase Ib study in selected advanced solid tumors. Safety, efficacy, and pharmacokinetics of birabresib were evaluated in patients with castrate-resistant prostate cancer, nuclear protein in testis midline carcinoma (NMC), and non-small-cell lung cancer.

  • Trial population in solid tumors: Of 46 treated patients, 26 had castrate-resistant prostate cancer, 10 had NMC, and 10 had non-small-cell lung cancer, from 47 patients enrolled.

  • Intervention model with parallel dose escalation: Patients received birabresib once daily at starting doses of 80 mg continuously (cohort A) or 100 mg for 7 consecutive days (cohort B) in 21-day cycles using a parallel dose escalation 3 + 3 design, with occurrence of dose-limiting toxicities (DLTs) and determination of the recommended phase II dose as the primary objective.

  • Recommended dosing and activity signal: The recommended phase II dose of birabresib in patients with select solid tumors is 80 mg once daily with continuous dosing, with dose-proportional increase in birabresib exposure and rapid absorption; three patients with NMC (80 mg once daily) had a partial response (Response Evaluation Criteria in Solid Tumors [RECIST] version 1.1) with duration of 1.4 to 8.4 months.

  • Additional solid-tumor evaluation: OTX015 is under evaluation in dose-finding studies in solid tumors, including GBM, supporting the rationale for the OTX015 Phase Ib (NCT02259114) in solid tumors, where NSCLC patients with rearranged ALK gene or KRAS-positive mutations are currently being treated.

Frequently Asked Questions

What is the mechanism of action of OTX015 in treating hematological malignancies?
OTX015 is a potent and selective bromodomain and extraterminal (BET) domain inhibitor. It targets the bromodomains of BET proteins, such as BRD2, BRD3, and BRD4, which are epigenetic readers involved in gene transcription. By inhibiting these proteins, OTX015 disrupts the expression of oncogenes crucial for the proliferation and survival of malignant cells in various hematological cancers. This mechanism leads to cell cycle arrest, apoptosis, and differentiation of cancer cells.
What is the potential therapeutic role of OTX015 within the current treatment paradigms for hematological malignancies?
OTX015 holds promise as a novel therapeutic agent for hematological malignancies, particularly in contexts where standard therapies have limited efficacy or resistance has developed. Its epigenetic mechanism of action offers a distinct approach compared to conventional chemotherapy or targeted agents. The drug could potentially be utilized as a monotherapy in specific subsets or as part of combination regimens to enhance efficacy and overcome resistance.
Are there specific patient populations or biomarkers that predict response to OTX015 in hematological malignancies?
Identifying specific patient populations and predictive biomarkers for OTX015 is an active area of research to optimize its clinical application. Certain hematological malignancies, such as acute myeloid leukemia (AML) and multiple myeloma, have shown particular sensitivity to BET inhibition. Biomarkers related to MYC expression, super-enhancer activity, or specific genetic mutations are being investigated to guide patient selection and predict therapeutic response.
What are the primary challenges or resistance mechanisms associated with OTX015 in hematological malignancy treatment?
Like many targeted therapies, OTX015 faces challenges related to intrinsic or acquired resistance mechanisms in hematological malignancies. These can involve alterations in downstream signaling pathways, compensatory epigenetic modifications, or mutations within the BET proteins themselves. Overcoming resistance often requires exploring combination strategies with other targeted agents or chemotherapy, or developing next-generation BET inhibitors.

References

  1. [1] Richter-Pechańska P, Kunz JB et al.. Pediatric T-ALL type-1 and type-2 relapses develop along distinct pathways of clonal evolution. Leukemia. 2022 Jul. 35585141
  2. [2] Lewin J, Soria JC et al.. Phase Ib Trial With Birabresib, a Small-Molecule Inhibitor of Bromodomain and Extraterminal Proteins, in Patients With Selected Advanced Solid Tumors. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2018 Oct 20. 29733771
  3. [3] Chotirat S, Thongnoppakhun W et al.. Molecular alterations of isocitrate dehydrogenase 1 and 2 (IDH1 and IDH2) metabolic genes and additional genetic mutations in newly diagnosed acute myeloid leukemia patients. Journal of hematology & oncology. 2012 Mar 7. 22397365
  4. [4] Melchor L, Brioli A et al.. Single-cell genetic analysis reveals the composition of initiating clones and phylogenetic patterns of branching and parallel evolution in myeloma. Leukemia. 2014 Aug. 24480973
  5. [5] Suguna E, Farhana R et al.. Acute Myeloid Leukemia: Diagnosis and Management Based on Current Molecular Genetics Approach. Cardiovascular & hematological disorders drug targets. 2018. 29766829
  6. [6] Savickiene J, Treigyte G et al.. The histone deacetylase inhibitor FK228 distinctly sensitizes the human leukemia cells to retinoic acid-induced differentiation. Annals of the New York Academy of Sciences. 2006 Dec. 17341629
  7. [7] Tabe Y. [Molecular diagnosis of and molecular targeting therapy for leukemia]. Rinsho byori. The Japanese journal of clinical pathology. 2009 Feb. 19317219
  8. [8] Chen D, Lu T et al.. Discovery, structural insight, and bioactivities of BY27 as a selective inhibitor of the second bromodomains of BET proteins. European journal of medicinal chemistry. 2019 Nov 15. 31461688
  9. [9] Bardini M, Woll PS et al.. Clonal variegation and dynamic competition of leukemia-initiating cells in infant acute lymphoblastic leukemia with MLL rearrangement. Leukemia. 2015 Jan. 24798483
  10. [10] Boi M, Gaudio E et al.. The BET Bromodomain Inhibitor OTX015 Affects Pathogenetic Pathways in Preclinical B-cell Tumor Models and Synergizes with Targeted Drugs. Clinical cancer research : an official journal of the American Association for Cancer Research. 2015 Apr 1. 25623213
  11. [11] Wartman LD, Larson DE et al.. Sequencing a mouse acute promyelocytic leukemia genome reveals genetic events relevant for disease progression. The Journal of clinical investigation. 2011 Apr. 21436584
  12. [12] Nakase K, Cheng J et al.. Mechanisms of SHP-1 P2 promoter regulation in hematopoietic cells and its silencing in HTLV-1-transformed T cells. Journal of leukocyte biology. 2009 Jan. 18948549
  13. [13] Khoury R, Raffoul C et al.. Precision Medicine in Hematologic Malignancies: Evolving Concepts and Clinical Applications. Biomedicines. 2025 Jul 7. 40722725
  14. [14] Riveiro ME, Astorgues-Xerri L et al.. OTX015 (MK-8628), a novel BET inhibitor, exhibits antitumor activity in non-small cell and small cell lung cancer models harboring different oncogenic mutations. Oncotarget. 2016 Dec 20. 27835869
  15. [15] Annereau M, Legrand FX et al.. Hospital-Compounded Birabresib Capsules for NUT Carcinoma: A Quality- and Risk-Based CMC Strategy. Pharmaceutical research. 2026 May. 41882454
  16. [16] West DS, Dogan A et al.. Clonally related follicular lymphomas and Langerhans cell neoplasms: expanding the spectrum of transdifferentiation. The American journal of surgical pathology. 2013 Jul. 23759932
  17. [17] Tasian SK, Bornhäuser M et al.. Targeting Leukemia Stem Cells in the Bone Marrow Niche. Biomedicines. 2018 Feb 21. 29466292
  18. [18] Thieblemont C, Molina T et al.. Optimizing therapy for nodal marginal zone lymphoma. Blood. 2016 Apr 28. 26989202
  19. [19] Yuan N, Wei W et al.. Young donor hematopoietic stem cells revitalize aged or damaged bone marrow niche by transdifferentiating into functional niche cells. Aging cell. 2023 Aug. 37226323
  20. [20] Kellner J, Liu B et al.. Fact or fiction--identifying the elusive multiple myeloma stem cell. Journal of hematology & oncology. 2013 Dec 7. 24314019

Contact Us

📍

Address

350 Springfield Avenue,
Suite #200 Summit, NJ 07901

✉️

For General Inquiry

info@pienomial.com

Related Posts